Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
Date:2/12/2008

secutive quarter and both combined to offset

performance shortfalls in our other units. Research Biotech made

continued progress toward its full long-term potential as the

activities we've added to boost sales growth for this unit helped it

deliver the 6% organic growth we had projected for the second half of

the year. And, SAFC turned in its highest reported quarterly sales

results of 2007, with contributions from both its core businesses and

2007 acquisitions;

-- Increasing reported and adjusted sales growth in CAPLA (Canada, Asia

Pacific and Latin America) markets by 23.3% and 11.0%, respectively, in

Q4 2007. Reported quarterly sales growth in our primary focus markets

of China, India and Brazil remained robust, with efforts to increase

our presence in all these markets through new sales initiatives. In

China, the construction of our first manufacturing site remains on

schedule;

-- Maintaining sales from web-based ordering through our industry-leading

web site at 40% of worldwide Q4 2007 Research based sales, enabling us

to meet our year end 2007 goal;

-- Beating our annual goal for savings from process improvement for the

6th consecutive year, with $15.2 million in reported savings. These

benefits, excluding the adverse impact of higher currency rates on

operating costs outside the U.S., were even more robust at

$22.3 million, continuing our long-term pattern of redirecting savings

to more productive, customer-facing activities; and

-- Continuing to successfully integrate exciting new capabilities in our

Research Biotech and SAFC business units. Efforts through our

partnership with Sangamo Biosciences to fully exploit their leadership

position in zinc finger protein technology are beginning to build a

pipeline of orders
'/>"/>

SOURCE Sigma-Aldrich Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. This ... development of sequencing technologies, and their applications. Current ... as companies developing them. Various applications of sequencing ...
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
(Date:9/2/2015)... September 2, 2015 BioLight ... or the "Company"), a firm that invests in, ... cancer diagnostics, announced today that presentations highlighting its ... be delivered at the Ophthalmology Futures European Forum ... of Cataract & Refractive Surgeons ("ESCRS"), both taking ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... conference call and webcast on Wednesday, October 28, at 5:00 ... , U.S. / Canada Dial-in Number: ... Participant Code: 51404008, Replay Dial-in ...
... Calif., Sept. 30 MacuSight, a developer of ... conditions, today provided a clinical development update for Perceiva, the ... patient enrollment in four ongoing Phase 2 clinical trials of ... the first half of 2010. All four studies are ...
... a number of key issues such as land use and ... global use of biofuels is excepted to more than double ... released today by Hart,s Global Biofuels Center. Leading the expansion ... use of more than 35%. Brazil will grow domestic supplies ...
Cached Biology Technology:BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET 2MacuSight(R) Provides Clinical Development Update for Perceiva(TM) 2MacuSight(R) Provides Clinical Development Update for Perceiva(TM) 3MacuSight(R) Provides Clinical Development Update for Perceiva(TM) 4MacuSight(R) Provides Clinical Development Update for Perceiva(TM) 5Global Biofuels Growth to Double by 2015 2Global Biofuels Growth to Double by 2015 3Global Biofuels Growth to Double by 2015 4
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... in the prestigious PLoS One journal changes our ... researchers found that degenerative changes and loss of vision are ... autophagy, in the fundus of the eye. The results ... of AMD, which currently lacks an efficient treatment. The University ...
... Monday following a big football game, fans of the ... and sugars, whereas supporters of the winning team opt ... Psychological Science , a journal of the Association ... that sport outcomes influence reckless driving, heart attacks, and ...
... 20, 2013  Today BluStor PMC, Inc. unveiled the ... protects the full stream of mobile security: device, ... what,s possible using BluStor, the company has launched ... http://www.blustor.com/whatspossible.php . (Logo:   http://photos.prnewswire.com/prnh/20130820/PH66368LOGO ) ...
Cached Biology News:Research breakthrough: Impaired autophagy associated with age-related macular degeneration 2For disappointed sports fans, defeats increase consumption of fat and sugar 2BluStor Introduces the World's First Platform to Protect the Full Stream of Mobile Security: Device, User, And Data 2
... DNA Polymerase I Large (Klenow) Fragment, ... that lacks both the 5´→3´ and the ... coli DNA Polymerase I (1,2). It is ... in strand displacement amplification (5). Klenow Fragment, ...
... one of several isoprostanes produced from arachidonic acid ... vasoconstrictor in the rat. 8-iso PGE2 inhibits U-46619 ... 0.5 and 5 µM, respectively. When infused into ... concentration of 4 mg/kg/min, 8-iso PGE2 decreases the ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
Biology Products: